Boehringer Ingelheim, a research-driven pharmaceutical company, agreed to acquire NBE Therapeutics, a clinical-stage Swiss biotechnology company, from PPF Group, a private equity firm, for €1.18bn ($1.43bn). The closing of the transaction is subject to customary closing conditions and is expected during the course of Q1 2021. “I am extremely proud of the NBE-Therapeutics’ team and delighted that our world class ADC expertise is being recognized by Boehringer Ingelheim. This transaction is a validation of our platform and its potential for the next generation cancer therapies. We look forward to progressing NBE-002, our lead program and best-in-class anti ROR1 ADC, and to continuing the fight against cancer alongside Boehringer Ingelheim with its strong clinical development capabilities,” Bertrand Damour, NBE Therapeutics. Chief Executive Officer.